ArticleBMC cancer2007
Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol.
Article in BMC cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 6 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women.Nature communications · 2017Pooled it
- Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Pooled it
- Identification of novel genetic markers of breast cancer survival.Journal of the National Cancer Institute · 2015Pooled it
- Common germline polymorphisms associated with breast cancer-specific survival.Breast cancer research : BCR · 2015Pooled it
- Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.Breast cancer research : BCR · 2015Pooled it
- A genome wide meta-analysis study for identification of common variation associated with breast cancer prognosis.PloS one · 2014Pooled it
- The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients.Oncotarget · 2015Trial
- Comparative analysis of distinct genomic landscapes in young-onset gBRCA1/2 breast cancer.JCI insight · 2026Article
- A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence.NPJ breast cancer · 2026Article
- Oncobiology and treatment of breast cancer in young women.Cancer metastasis reviews · 2022Review
- Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers.The journal of pathology. Clinical research · 2020Article
- Pathogenic Variants inJCO precision oncology · 2020Article
- Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).The journal of pathology. Clinical research · 2019Article
- Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35-39 at Increased Familial Risk of Breast Cancer.EClinicalMedicine · 2019Article
- Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study.Breast cancer research : BCR · 2018Article
- Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.The Lancet. Oncology · 2018Article
- Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer: The POSH Observational Cohort Study.Annals of surgery · 2017Observational
- Quantifying the cumulative effect of low-penetrance genetic variants on breast cancer risk.Molecular genetics & genomic medicine · 2015Article
- An evaluation of the prognostic model PREDICT using the POSH cohort of women aged ⩽40 years at breast cancer diagnosis.British journal of cancer · 2015Article
- Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.The pharmacogenomics journal · 2015Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundYoung women presenting with breast cancer are more likely to have a genetic predisposition to the disease than breast cancer patients in general. A genetic predisposition is known to increase the risk of new primary breast (and other) cancers. It is unclear from the literature whether genetic status should be taken into consideration when planning adjuvant treatment in a young woman presenting with a first primary breast cancer. The primary aim of the POSH study is to establish whether genetic status influences the prognosis of primary breast cancer independently of known prognostic factors. METHODS/
designThe study is a prospective cohort study recruiting 3,000 women aged 40 years or younger at breast cancer diagnosis; the recruiting period covers 1st June 2001 to 31st December 2007. Written informed consent is obtained at study entry. Family history and known epidemiological risk data are collected by questionnaire. Clinical information about diagnosis, treatment and clinical course is collected and blood is stored. Follow up data are collected annually after the first year. An additional recruitment category includes women aged 41 to 50 years who are found to be BRCA1 or BRCA2 gene carriers and were diagnosed with their first breast cancer during the study recruiting period. DISCUSSION: Power estimates were based on 10% of the cohort carrying a BRCA1 gene mutation. Preliminary BRCA1 and BRCA2 mutation analysis in a pilot set of study participants confirms we should have 97% power to detect a difference of 10% in event rates between gene carriers and sporadic young onset cases. Most of the recruited patients (>80%) receive an anthracycline containing adjuvant chemotherapy regimen making planned analyses more straightforward.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.